ProQR Therapeutics
PRQR
55 hedge funds and large institutions have $47.5M invested in ProQR Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 8 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 4
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
20% more funds holding
Funds holding: 46 → 55 (+9)
4.22% more ownership
Funds ownership: 23.4% → 27.62% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $60M → $47.5M (-$12.4M)
26% less call options, than puts
Call options by funds: $705K | Put options by funds: $950K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.87M |
| 2 |
Millennium Management
New York
|
+$3.43M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.88M |
| 4 |
Morgan Stanley
New York
|
+$826K |
| 5 |
JP Morgan Chase
New York
|
+$675K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.47M |
| 2 |
AIC
AWM Investment Company
New York
|
-$617K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$504K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$381K |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$359K |
PRQR Hedge Fund Activity: Q1 2023 in Review
55 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2023, worth a combined $47.5M — down 21% from $60M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PRQR positions and 8 closed out — a net gain of 9 holders — while 18 added to existing stakes and 4 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.87M. The largest seller was Opaleye Management, cutting an estimated $2.47M.
- 55 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2023, up from 46 in Q4 2022.
- Funds reported $47.5M of ProQR Therapeutics stock for Q1 2023, down 21% quarter-over-quarter.
- 17 funds opened new ProQR Therapeutics positions in Q1 2023 and 8 closed out, a net change of +9 holders.
- The largest ProQR Therapeutics buyer in Q1 2023 was EcoR1 Capital, an estimated $8.87M added.
- The largest ProQR Therapeutics seller in Q1 2023 was Opaleye Management, an estimated $2.47M sold.
Based on aggregated 13F filings for Q1 2023.